ACACA and metabolic dysfunction-associated steatotic liver disease: Long term treatment with ACC inhibitors (21 days) significantly reduced high-fat sucrose diet-induced hepatic steatosis, and alleviated diet-induced nonalcoholic fatty liver disease and hepatic insulin resistance in rats [3].